TB-500
TB-500 is a synthetic peptide derived from the active region of thymosin beta-4 (Tβ4), a naturally occurring peptide with various biological functions, including promoting wound healing and tissue regeneration.
Here's a more detailed breakdown:
What it is:
TB-500 is a synthetic peptide, specifically Ac-LKKTETQ, derived from the active region of thymosin β4 (Tβ4).
Biological functions:
The unacetylated form (LKKTETQ) of Tβ4 has various biological functions, including actin binding, dermal wound healing, angiogenesis (formation of new blood vessels), and skin repair.
Research and Applications:
Wound Healing: Tβ4 has been shown to accelerate dermal healing in various animal models and has been used in clinical trials for stasis and pressure ulcers.
Tissue Regeneration: Tβ4 promotes cell migration, stem cell mobilization and differentiation, and inhibits inflammation, apoptosis, and infection, contributing to tissue regeneration.
Other Potential Uses: Research is ongoing into the peptide's regenerative power in the infected or injured eye (Pseudomonas aeruginosa-induced keratitis, corneal wound healing) and its potential as a doping agent to enhance performance and skeletal muscle regeneration.
Doping Control:
Due to its potential to enhance performance and muscle regeneration, TB-500 has emerged as a veterinary preparation, and there are reports of its use in horses. Methods for doping control analysis of TB-500 and its metabolites have been developed.
Misbranded Products:
It's important to note that numerous websites attempt to commercialize products like TB-500 without proper approval, and these products may be misbranded or adulterated.
Safety Concerns:
Due to the lack of official control over the production of these substances and the absence of approval by health authorities, the administration of such products is dangerous.
What is TB500 (Thymosin Beta-4)
TB-500, also known as Thymosin Beta 4, is a synthetic peptide derived from a naturally occurring protein found in most mammalian tissues1. This peptide is known for stimulating muscle growth, regeneration, and wound healing3. In research, TB500 (Thymosin Beta-4) has been identified as a key mediator in cellular proliferation and differentiation, as well as a modulator of the inflammatory response. Researchers have found that TB500 (Thymosin Beta-4) is a potent promoter of wound healing3 and modulator of the inflammatory response of animal test subjects4. Its ability to regulate the production of actin, a crucial component for cellular structure and movement, highlights its broad spectrum of beneficial capabilities in various biological processes.
Effects of TB-500 Demonstrated in Recent Studies
Recent studies on TB-500 (Thymosin Beta 4) have shown potential benefits, including promoting endothelial cell differentiation, angiogenesis in dermal tissues, and keratinocyte migration. The peptide may also enhance collagen deposition, reduce joint inflammation, increase muscle growth, and improve muscle tone and endurance. Additionally, TB500 (Thymosin Beta-4) has been found to relax muscle spasms, promote tissue repair, increase cellular exchange, and help maintain flexibility by stretching connective tissue. It also aids in preventing the formation of adhesions and fibrous bands in muscles, tendons, and ligaments.
Purely for Scientific Research
While significant research has been conducted on TB500 (Thymosin Beta-4), it is crucial to note that this peptide is intended solely for scientific study. Any findings or observations related to TB-500’s functionality, mechanics, or benefits should be derived exclusively from controlled research environments.
Muscle Repair and Maintenance – TB500
TB500 (Thymosin Beta-4) has been researched extensively in the areas of muscle and connective tissue repair5. TB500 (Thymosin Beta-4) has been shown to stimulate the overproduction of regenerative fibers following injury, thereby speeding the process of recovery with minimal inflammation and residual scarification.
TB500’s property of enhancing muscle growth in both healthy and damaged tissues has led to its application as an experimental therapeutic in animal test subjects with muscular dystrophy6. Regular administration of TB500 (Thymosin Beta-4) allowed animal test subjects with muscular dystrophy to achieve much improved maintenance of muscle growth and development, even in the absence of important, naturally occurring proteins that usually guide this action.
TB500 (Thymosin Beta-4) has also been researched to be an aid in the healing of heart tissue following heart attack7 and as a very powerful agent for quickly healing skin abrasions. TB500’s angiogenic (blood vessel-forming) properties8 are responsible for its excellent application in these areas.
Research products only, they are not for human consumption.
Synonyms:
Thymosin Beta 4; TB500; TB-500
Peer-Reviewed Sources:
Safer, D., Elzinga, M., & Nachmias, V. T. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 266(7), 4029-4032.
Grant, D. S., Kinsella, J. L., Kibbey, M. C., LaFlamme, S., Burbelo, P. D., Goldstein, A. L., & Kleinman, H. K. (1995). Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. Journal of cell science, 108(12), 3685-3694.
Malinda, K. M., Sidhu, G. S., Mani, H., Banaudha, K., Maheshwari, R. K., Goldstein, A. L., & Kleinman, H. K. (1999). Thymosin β4 accelerates wound healing. Journal of investigative dermatology, 113(3), 364-368.
Sosne, G., Szliter, E. A., Barrett, R., Kernacki, K. A., Kleinman, H., & Hazlett, L. D. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental eye research,74(2), 293-299.
Blain, E. J., Mason, D. J., & Duance, V. C. (2002). The effect of thymosin beta4 on articular cartilage chondrocyte matrix metalloproteinase expression. Biochemical Society Transactions, 30(Pt 6), 879-882.
Spurney, C. F., Cha, H. J., Sali, A., Pandey, G. S., Pistilli, E., Guerron, A. D., & Nagaraju, K. (2010). Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PloS one, 5(1), e8976.
Crockford, D. (2007). Development of thymosin β4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences, 1112(1), 385-395.
Smart, N., Rossdeutsch, A., & Riley, P. R. (2007). Thymosin β4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis, 10(4), 229-241.
ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.